Brigatinib (Alunbrig) for Non-Small Cell Lung Cancer (online only)
Date: April 23, 2018
Issue #:
1545Summary:
The FDA has approved brigatinib (Alunbrig– Takeda),
an oral tyrosine kinase inhibitor, for treatment of
patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC)
who have progressed on or are intolerant to crizotinib(Xalkori). Translocations of the ALK gene are found in
about 5% of lung cancers; they occur predominantly
in nonsmokers with adenocarcinoma. Brigatinib is the
third tyrosine kinase inhibitor to be approved for this
indication; ceritinib(Zykadia) and alectinib(Alecensa)
were approved earlier, and subsequently were approved
for first-line treatment as well. Loratinib, another oral
tyrosine kinase inhibitor, is currently under review by
the FDA for treatment of ALK-positive NSCLC.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: admin Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Drugs & Pharmacology | Genetics | Lung Cancer | Lymphoma | Non-Small Cell Lung Cancer | Oral Cancer